Abstract

Fibrolamellar carcinoma (FLC) is a rare liver cancer. FLCs uniquely produce DNAJ-PKAc, a chimeric enzyme consisting of a chaperonin-binding domain fused to the Ca subunit of protein kinase A. Biochemical analyses of clinical samples reveal that a unique property of this fusion enzyme is the ability to recruit heat shock protein 70 (Hsp70). This cellular chaperonin is frequently up-regulated in cancers. Gene-editing of mouse hepatocytes generated disease-relevant AML12DNAJ-PKAc cell lines. Further analyses indicate that the proto-oncogene A-kinase anchoring protein-Lbc is up-regulated in FLC and functions to cluster DNAJ-PKAc/Hsp70 sub-complexes with a RAF-MEK-ERK kinase module. Drug screening reveals Hsp70 and MEK inhibitor combinations that selectively block proliferation of AML12DNAJ-PKAc cells. Phosphoproteomic profiling demonstrates that DNAJ-PKAc biases the signaling landscape toward ERK activation and engages downstream kinase cascades. Thus, the oncogenic action of DNAJ-PKAc involves an acquired scaffolding function that permits recruitment of Hsp70 and mobilization of local ERK signaling.

Data availability

There are no restrictions to the availability of our data. Raw mass spectrometry data has been uploaded to MassIVE, an NIH supported MS data repository (MSV000083167). Data will be made publicly available.

The following data sets were generated

Article and author information

Author details

  1. Rigney E Turnham

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. F Donelson Smith

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8080-7589
  3. Heidi L Kenerson

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Mitchell H Omar

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Martin Golkowski

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Irvin Garcia

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Renay Bauer

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Ho-Tak Lau

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Kevin M Sullivan

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Lorene K Langeberg

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3760-7813
  11. Shao-En Ong

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Kimberly J Riehle

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Raymond S Yeung

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. John D Scott

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    For correspondence
    scottjdw@uw.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0367-8146

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (R01DK119192)

  • John D Scott

Fibrolamellar Cancer Foundation

  • John D Scott

National Cancer Institute (R21CA201867)

  • Kimberly J Riehle

St. Baldrick's Foundation

  • Kimberly J Riehle

National Cancer Institute (R21CA177402)

  • Shao-En Ong

NIH Office of the Director (S10 OD021502)

  • Shao-En Ong

National Institutes of Health (2T32CA080416)

  • Rigney E Turnham

National Institute of Diabetes and Digestive and Kidney Diseases (F32DK121415)

  • Mitchell H Omar

Fibrolamellar Cancer Foundation

  • Raymond S Yeung

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2019, Turnham et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,035
    views
  • 344
    downloads
  • 50
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rigney E Turnham
  2. F Donelson Smith
  3. Heidi L Kenerson
  4. Mitchell H Omar
  5. Martin Golkowski
  6. Irvin Garcia
  7. Renay Bauer
  8. Ho-Tak Lau
  9. Kevin M Sullivan
  10. Lorene K Langeberg
  11. Shao-En Ong
  12. Kimberly J Riehle
  13. Raymond S Yeung
  14. John D Scott
(2019)
An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma
eLife 8:e44187.
https://doi.org/10.7554/eLife.44187

Share this article

https://doi.org/10.7554/eLife.44187

Further reading

    1. Biochemistry and Chemical Biology
    Shu-Ting Zhang, Shi-Kai Deng ... Ning-Yi Zhou
    Research Article

    1-Naphthylamine (1NA), which is harmful to human and aquatic animals, has been used widely in the manufacturing of dyes, pesticides, and rubber antioxidants. Nevertheless, little is known about its environmental behavior and no bacteria have been reported to use it as the growth substrate. Herein, we describe a pathway for 1NA degradation in the isolate Pseudomonas sp. strain JS3066, determine the structure and mechanism of the enzyme NpaA1 that catalyzes the initial reaction, and reveal how the pathway evolved. From genetic and enzymatic analysis, a five gene-cluster encoding a dioxygenase system was determined to be responsible for the initial steps in 1NA degradation through glutamylation of 1NA. The γ-glutamylated 1NA was subsequently oxidized to 1,2-dihydroxynaphthalene which was further degraded by the well-established pathway of naphthalene degradation via catechol. A glutamine synthetase-like (GS-like) enzyme (NpaA1) initiates 1NA glutamylation, and this enzyme exhibits a broad substrate selectivity toward a variety of anilines and naphthylamine derivatives. Structural analysis revealed that the aromatic residues in the 1NA entry tunnel and the V201 site in the large substrate-binding pocket significantly influence NpaA1’s substrate preferences. The findings enhance understanding of degrading polycyclic aromatic amines, and will also enable the application of bioremediation at naphthylamine contaminated sites.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qiong He, Miao-Miao Zhao ... Jin-Kui Yang
    Research Article

    Diabetes, a prevalent chronic condition, significantly increases the risk of mortality from COVID-19, yet the underlying mechanisms remain elusive. Emerging evidence implicates Cathepsin L (CTSL) in diabetic complications, including nephropathy and retinopathy. Our previous research identified CTSL as a pivotal protease promoting SARS-CoV-2 infection. Here, we demonstrate elevated blood CTSL levels in individuals with diabetes, facilitating SARS-CoV-2 infection. Chronic hyperglycemia correlates positively with CTSL concentration and activity in diabetic patients, while acute hyperglycemia augments CTSL activity in healthy individuals. In vitro studies reveal high glucose, but not insulin, promotes SARS-CoV-2 infection in wild-type cells, with CTSL knockout cells displaying reduced susceptibility. Utilizing lung tissue samples from diabetic and non-diabetic patients, alongside Leprdb/dbmice and Leprdb/+mice, we illustrate increased CTSL activity in both humans and mice under diabetic conditions. Mechanistically, high glucose levels promote CTSL maturation and translocation from the endoplasmic reticulum (ER) to the lysosome via the ER-Golgi-lysosome axis. Our findings underscore the pivotal role of hyperglycemia-induced CTSL maturation in diabetic comorbidities and complications.